Publications by authors named "Zach Sergi"
A patient-derived cell model for malignant transformation in IDH-mutant glioma.
Acta Neuropathol Commun
September 2024
Article Synopsis
- The study focuses on malignant transformation (MT) in IDH-mutant gliomas, emphasizing the need to understand the mechanisms behind MT and intervene at early stages.
- Researchers created two 3D cell models (403L and 403H) from the same patient's IDH-mutant glioma, representing low-grade (LGG) and high-grade (HGG) tumors, allowing for comparison of genetic and metabolic changes.
- The findings indicate that the high-grade model (403H) is more aggressive, showing increased cell invasion and distinct metabolic alterations, providing a new framework for investigating MT in gliomas.
Article Synopsis
- - The study identifies zotiraciclib (ZTR) as a potent treatment for IDH-mutant gliomas, showing it selectively inhibits their growth through a targeted approach.
- - ZTR works by suppressing key proteins involved in cell function, leading to mitochondrial dysfunction, reduced NAD+ production, and increased oxidative stress.
- - These findings have prompted a clinical trial (NCT05588141) to explore the effectiveness of ZTR in treating patients with IDH-mutant gliomas, reflecting a move toward precision medicine.
Article Synopsis
- Deletions or mutations in the PTEN gene are common in glioblastoma (GBM) and lead to issues with DNA damage repair; this study investigates whether PTEN deficiency creates a weakness against combined DNA damage and repair suppression using specific inhibitors.
- Researchers treated different GBM cell lines with the drug LMP400 (a TOP1 inhibitor) alone and with either PARP inhibitors (Olaparib or Niraparib) and found that PTEN-null cells are significantly more sensitive to this treatment.
- The combination of LMP400 and Niraparib not only increases cell death in PTEN-deficient glioma cells but also shows promise in animal models for penetrating the blood-brain barrier and improving survival, supporting the
Most tumors, including brain tumors, are sporadic. However, a small subset of CNS tumors are associated with hereditary cancer conditions like Lynch Syndrome (LS). Here, we present a case of an oligodendroglioma, IDH-mutant and 1p/19q-codeleted, and LS with a germline pathogenic mutation.
View Article and Find Full Text PDF